In this article
The short answer
Omnibus VIII, Regulation (EU) 2026/78, had no sell-through period because it contained no transitional clause at all. It simply applied from 1 May 2026. Since the annex rules govern what a product may contain, every unit supplied in the EU or Northern Ireland from that day had to comply, including stock already with distributors and retailers. Great Britain did give windows: under SI 2026/109, hexyl salicylate stock placed before 15 August 2026 can be sold until the end of 14 February 2027, and the CMR and silver bans apply from 23 March 2027, with older stock sellable until the end of 22 September 2027.
Key takeaways
- Placing on the market is the first supply of a unit. Making available is any supply, paid or free. Sell-through windows are built from the gap between the two dates.
- Regulation (EU) 2026/78 just says it applies from 1 May 2026, with no transitional clause, so old stock had to comply from that day.
- Recital 24 explains why: the cosmetics changes were set to apply from the same date as the CMR classifications in Delegated Regulation (EU) 2024/2564.
- The rule lands on whoever is supplying, so distributors and retailers hold the exposure, and your contract decides who pays.
- Northern Ireland follows the EU answer. Great Britain's mirror instrument is SI 2026/109, with windows to 14 February 2027 and 22 September 2027.
- EU-blocked stock moved into GB now is placed on the GB market now, so it must meet today's GB rules. Perfume oils with hexyl salicylate and CI 77820 nail products often do.
- Relabelling never fixes a prohibited composition. Record every stock decision with dates and quantities in or beside the PIF.
In the first week of May, one of our clients forwarded us an email from a retailer in the Netherlands. It listed a few dozen product codes and said, in effect: these are blocked, please arrange collection and a credit note. Every code contained a fragrance with hexyl salicylate above the new limits. The stock had been delivered in March, paid for, and was sitting in a store room. Nothing about the products had changed except the date.
That is what Omnibus VIII no sell-through means in practice. Regulation (EU) 2026/78 did not give anyone time to sell down old stock, so stock already in the chain on 1 May 2026 had to meet the new rules on that day. What the regulation banned and restricted is covered in our guide to the Omnibus VIII CMR ban and, line by line, in our plain-English reading of Regulation (EU) 2026/78. This article is about the stock: why the rule worked that way, who ends up paying, and what you can still lawfully do with units that are now stuck, six months on.
The two words every transitional clause turns on
Article 2 of Regulation (EC) No 1223/2009 defines two terms that sound interchangeable and are not.
- Making available on the market is any supply of a cosmetic product for distribution, consumption or use on the market in the course of a commercial activity, whether in return for payment or free of charge. Your shipment to a wholesaler is making available. So is the wholesaler's delivery to a shop, the shop's sale to a customer and the free sample in a goody bag.
- Placing on the market is the first making available. It happens once per unit, when that unit first leaves you for the market.
A transitional clause uses those two terms to build a window. One date stops new units being placed on the market. A later date stops older units being made available at all. Between the two, stock that was already out in the chain can be sold through. Great Britain's version of the regulation uses the same definitions, with "the market of Great Britain" in place of the Community market, so the logic carries across both systems.
Two details catch people. First, "free of charge" is in the definition, so giving stock away, using it as a gift with purchase or handing it to a charity is still making it available. Second, stock that never left your own warehouse before a placing date was never placed on the market. That matters every time a measure does have a window, as the fragrance allergen rules showed this summer.
What Regulation (EU) 2026/78 actually says about stock
Nothing. That is the whole point. The operative text is two short articles. Article 1 amends Annexes II, III, IV and V. Article 2 says the regulation enters into force on the twentieth day after publication and "shall apply from 1 May 2026". It was published in the Official Journal on 13 January 2026, so it entered into force on 2 February 2026. There is no sentence about placing on the market, none about making available, and no transitional provision of any kind.
Silence works against the stock because of how the annexes bite. Article 14 of the cosmetics regulation says cosmetic products shall not contain prohibited substances in Annex II, or restricted substances used outside their Annex III conditions. It is a rule about what is in the product, not about when the product was made. Distributors, for their part, must not make available a product they believe is not in conformity (Article 6(3)). So once the annexes changed, every unit supplied from 1 May 2026 had to meet them, whatever its batch date. A sell-through window only exists when the legislator writes one in.
Why didn't the Commission write one? Recital 24 gives the reason: the amendments based on the new CMR classifications "should apply from the same date as those classifications". The classifications came from Delegated Regulation (EU) 2024/2564, the chemicals classification update, which was published on 30 September 2024 and applies from 1 May 2026. Article 15 of the cosmetics regulation prohibits classified CMR substances unless a specific use has been found safe, so the Commission lined the cosmetics annexes up with the classification date instead of leaving a gap in which a classified substance stayed on shelves. The industry had about 19 months' notice of the classification, and a little under four months' notice of the cosmetics text itself.
We have checked for later EU amendments to the cosmetics regulation. The only one since 2026/78 is Regulation (EU) 2026/909, and it adds no transitional arrangement for the Omnibus VIII substances. As of 20 November 2026 there is still no sell-through for them.
How other recent measures handled stock, side by side
The quickest way to see that the silence was a choice is to put Omnibus VIII next to measures that did spell out their dates.
| Measure | What it changed | Last day to place on the market | Last day old stock may be made available |
|---|---|---|---|
| Regulation (EU) 2026/78 (Omnibus VIII), EU and NI | CMR bans and restrictions, including hexyl salicylate and silver | No separate date: applies from 1 May 2026 | None. No transitional clause, so stock had to comply from 1 May 2026 |
| Regulation (EU) 2024/858, EU and NI | Colloidal silver (nano) ban, Annex II entry 1727 | 31 January 2025 (not placed from 1 February 2025) | 31 October 2025 (not made available from 1 November 2025) |
| Regulation (EU) 2023/1545, EU and NI | Expanded fragrance allergen labelling | Until 31 July 2026 | Until 31 July 2028, for units placed before 31 July 2026 |
| SI 2026/109, Great Britain | Hexyl salicylate limits (Annex 3 entry 325) | Before 15 August 2026 | Until the end of 14 February 2027 |
| SI 2026/109, Great Britain | CMR bans incl. silver nano and massive (Annex 2 entries 1761 to 1773) | Before 23 March 2027 | Until the end of 22 September 2027 |
| SI 2026/23, Great Britain | 4-MBC ban and formaldehyde-releaser warning threshold | Before 15 July 2026 | Until the end of 14 January 2027 |
| SI 2026/23, Great Britain | A separate CMR list, incl. TPO (Annex 2 entries 1745 to 1760) | Before 15 August 2026 | Until the end of 14 February 2027 |
Two lessons fall out of that table. The EU can and does write two-date clauses, as it did for the nano ban and the allergen labelling change, so "there is always a grace period" is simply wrong. And Great Britain wrote two dates into both of its 2026 instruments. Be careful with the GB rows, though. The GB instrument that mirrors most of Omnibus VIII is SI 2026/109, not SI 2026/23. SI 2026/23 deals with 4-MBC, the formaldehyde-releaser warning and a separate CMR list. Mixing the two up is how stock instructions end up with the wrong date on them. Our overview of the UK cosmetic regulation changes for 2026 covers both.
Who is on the hook for stock still in the chain
Because the rule attaches to every act of supply, it lands on whoever is holding the stock. That is often not the brand.
| Who | What the regulation asks of them | Where they usually stand on stock |
|---|---|---|
| Responsible Person (brand or importer) | Ensures compliance with Article 14, the annex rules. If a product it placed on the market is not in conformity, it takes corrective action, withdraws or recalls as appropriate (Article 5(2)) | Owns the formula and the decision. Usually carries the cost, unless a contract says otherwise |
| Distributor (wholesaler, retailer, marketplace seller) | Must not make available a product it believes is not in conformity, and must make sure corrective action, withdrawal or recall is taken for units it has supplied (Article 6(3)) | Holds the physical stock and the exposure for its own sales, so it will come back to the brand for a credit |
| Competent authority | Can require the Responsible Person to bring products into conformity, withdraw or recall them, within a set time, where the annex restrictions are breached (Article 25(1)(f)) | Expects to see a decision, the date it was taken and the quantities |
The commercial lesson is the one our client learned from that retailer. The regulation decides who must stop selling. Your contract decides who pays for it. A distributor told in February had time to stop reordering and run its own stock down. A distributor told in May had a credit claim. If your distribution agreements are silent on regulatory withdrawals, fix that clause now, before the next instrument, because it costs very little to agree while nothing is at stake.
Six months on: a decision tree for stock you are still holding
We still get calls about Omnibus VIII stock: returns that came back from retailers, pallets in a third-party warehouse, consignment stock nobody counted. Work through it in this order, because the cheap options come first.
- Identify by formula, not by range. One fragrance compound can sit across three ranges. A supplier who changed the compound mid-year can leave you with clean later batches and blocked earlier ones. Use the batch records and the supplier's statements, and check the actual level against the entry, not just whether the substance appears.
- Find every unit. Your warehouse, the fulfilment partner, marketplace fulfilment centres, distributor and retailer stock, consignment stock, samples, gift-with-purchase stock, PR kits and the trade show boxes. The last five are the ones brands forget.
- Block it in the system. Put the affected SKUs on hold in the warehouse management system and on every sales channel. An email to the team does not stop an automated order from shipping.
- Sort by destination. Northern Ireland follows the EU cosmetics rules, so NI stock gets the EU answer. Great Britain is a separate question, covered below. Markets outside the UK and EU have their own lists.
- Choose an outcome per group. Rework is rarely realistic for a filled fragrance product. Relabelling never cures a prohibited or over-limit composition. That leaves redirecting to a market where the product is lawful, returning to a supplier where the contract allows, or destruction.
- Write it down. Record the decision, the date, the quantities and the reasoning, and keep it with the product information file. If an officer asks why a product was on a shelf in June, you want to hand over a dated decision, not a recollection.
If step one is the hard part, that is what our restricted ingredients check is for. Reformulated products going back on sale need the composition work and the safety report finished before anything is printed, and our guide to the CPSR review cycle sets out when a report has to be reopened.
Can the stock go to Great Britain instead?
Often, yes, and this is where most of the value in blocked stock is recovered. The thing to get right is the date logic. GB's transitional clauses protect units that were placed on the GB market before the GB date. EU stock you move into Great Britain now is being placed on the GB market now, so it has to meet the GB rules as they stand today. It gets no credit for having been made before any deadline.
| Stock blocked in the EU because of | Can it be newly placed on the GB market today? | GB deadline to watch |
|---|---|---|
| Hexyl salicylate above the EU limit | Only if the level meets GB Annex 3 entry 325. A perfume oil at 1.5% fails the EU 0.3% leave-on figure but sits inside the GB 2% fragrance line | Units placed in GB before 15 August 2026 that miss entry 325 can be sold until the end of 14 February 2027 |
| Silver (nano) or silver (massive) | Massive: yes, until 22 March 2027. Nano: only if already notified in GB, because nano notification is due six months before placing | Placed before 23 March 2027, sellable until the end of 22 September 2027 |
| Silver powder or CI 77820 outside the EU product types | Yes. GB has no silver powder limit and no product-type limit on CI 77820 | None as of 20 November 2026 |
| Another substance added to EU Annex II by 2026/78 | Check it by CAS number against Schedule 1 of SI 2026/109. If listed and not restricted elsewhere in GB, placing is open until 22 March 2027 | If listed, sellable until the end of 22 September 2027 |
The hexyl salicylate row is the one we use most. A roll-on perfume oil at 1.5% hexyl salicylate has been over the EU limit since 1 May 2026, because a non-alcohol fragrance falls under the 0.3% leave-on line. In Great Britain the fragrance line covers spray and non-spray products at 2%, so the same oil can be lawfully placed there today. Our hexyl salicylate limits by product type has the full comparison. Silver works the same way for CI 77820 in nail polish or highlighter, as our silver ingredient checker shows.
Redirecting is not just a matter of changing the delivery address. The product needs a GB Responsible Person, a GB address on the label, a notification on the UK portal before it goes on sale and a safety report that covers GB. For nanomaterials, GB still requires notification six months before placing (Article 16). That is why nano silver is not a realistic route unless it was already notified: a fresh notification today could not be completed before the 23 March 2027 ban.
For markets outside the UK and EU, our reading is that supply for use in a third country is not making available on the EU market, so export can be a lawful outlet. Check the destination's own ingredient rules first, and keep the shipping records with your stock decision.
Withdrawal, recall, and what to write down
The regulation defines the two terms precisely. A withdrawal is any measure aimed at preventing the making available of a product that is in the supply chain. A recall is any measure aimed at getting back a product that has already been made available to the end user. Using the wrong word in a letter to a retailer or an authority causes confusion you do not need.
Omnibus VIII stock is normally a withdrawal question. Regulation 2026/78 says nothing about units consumers bought before 1 May 2026, and those units were lawful when they were sold. Our reading is that the regulation itself does not require you to recall them. Articles 5(2) and 6(3) still ask for corrective action, withdrawal or recall "as appropriate", so the decision is yours to take and record, ideally with your safety assessor's view on whether the product presents a risk. Where it does, the Responsible Person must also inform the competent authorities.
The practical steps, including who to tell and which records to keep, are in our guide to cosmetic product recalls and withdrawals. If an officer is already asking, our article on trading standards inspections explains what the visit looks like. Any reformulation also means updating the notification, which our guide to updating a CPNP notification after a regulatory change walks through.
Reading the next measure for its supply language
There will be another omnibus. The CMR classifications come in rounds, and the cosmetics annexes follow them. Before you read the next one for its substances, read the last article for its dates. If it says "shall apply from" and nothing else, treat it as an off-shelf date for every unit in the chain. If it names a placing date and a later making-available date, you have a window, and the window only covers units that left you before the first date.
Three habits make the next one cheaper. Keep a live map of which fragrance compounds and functional ingredients sit in which products, so the identification step takes an afternoon. Watch the classification pipeline rather than the cosmetics annexes, because the classification is where your notice period really starts. And give trade customers written notice, with product codes, as early as you can. Our overview of the 2026 cosmetic regulation changes keeps the dates for this year in one place.
Holding stock you are not sure you can supply?
Send us the formulas, the batch list and where the units are sitting. We check each product against the EU annexes and the GB instruments, tell you which units are blocked in which market, which can still be placed in Great Britain and until when, and what to record so the decision stands up if an inspector asks.
Related reading
- EU Omnibus VIII (Regulation 2026/78): what it bans
- Regulation (EU) 2026/78 in plain English, entry by entry
- Hexyl salicylate limits by product type, EU and GB
- Silver in cosmetics after the 2026 ban
- UK cosmetic regulation changes 2026
- Fragrance allergen deadline checklist
- Cosmetic product recalls and withdrawals: what to do
- All regulatory compliance articles
Myths we hear
- Every regulatory change comes with a sell-through period. Only when the legislator writes one in. Regulation (EU) 2026/78 has none, while 2024/858 and 2023/1545 spelled out two dates.
- Stock that was already placed on the market can always be sold through. Only where the measure protects it. Without a transitional clause, the annex rules apply to every act of supply, including yours to a retailer and theirs to a customer.
- Giving the stock away avoids the problem. Making available covers supply free of charge, so samples, gifts with purchase and donations in the EU are still caught.
- SI 2026/23 is the GB version of Omnibus VIII. The GB mirror for hexyl salicylate, silver and most of the Omnibus VIII substances is SI 2026/109. SI 2026/23 covers 4-MBC, the formaldehyde-releaser warning and a separate CMR list.
- If it cannot be sold in the EU, it has to be destroyed. Not necessarily. Much of it can be placed in Great Britain under the current GB rules, or exported where the destination allows it, provided the paperwork is in place.
What to do this week
- Pull every product containing an Omnibus VIII substance and check the actual level against the EU entry, batch by batch.
- Count every unit: own warehouse, fulfilment partners, marketplace centres, distributors, retailers, consignment, samples, gift-with-purchase and PR stock.
- Put affected SKUs on hold in the warehouse system and on every sales channel, so nothing ships by default.
- Keep Northern Ireland stock with the EU answer and treat Great Britain separately.
- For each blocked group, check whether it meets the GB rules today, and if it does, line up the GB Responsible Person, label, notification and safety report before moving it.
- Diary the GB dates: 14 February 2027 for hexyl salicylate stock placed before 15 August 2026, 23 March 2027 and 22 September 2027 for the GB CMR and silver bans.
- Record each decision, with quantities, dates and reasons, in or beside the product information file.
- Add a regulatory withdrawal clause to your distribution agreements before the next omnibus arrives.
Frequently asked questions
Why did Omnibus VIII have no sell-through period?
Because Regulation (EU) 2026/78 contains no transitional clause. It simply applies from 1 May 2026. Recital 24 says the CMR-based changes should apply from the same date as the classifications in Delegated Regulation (EU) 2024/2564, which also apply from 1 May 2026.
What is the difference between placing on the market and making available?
Placing on the market is the first supply of a unit onto the market and happens once. Making available is any supply in the course of a commercial activity, paid or free, including every step down the chain. Sell-through windows use the gap between the two dates.
Can I still sell stock I made before 1 May 2026 in the EU?
Not if it fails the new entries. With no transitional clause, the annex rules apply to every unit supplied in the EU or Northern Ireland from 1 May 2026, whenever it was made or first sold. Stock that meets the new limits is unaffected.
Does Great Britain have a sell-through period for the same substances?
Yes. Under SI 2026/109, hexyl salicylate products placed in GB before 15 August 2026 can be sold until the end of 14 February 2027. The GB CMR and silver nano and massive bans apply from 23 March 2027, with older stock sellable until the end of 22 September 2027.
Can I move EU-blocked stock to Great Britain?
Often, if it meets the GB rules as they are today, because moving it now counts as placing it on the GB market now. It also needs a GB Responsible Person, a GB label address, a UK notification and a safety report covering GB.
Do I have to recall products customers bought before 1 May 2026?
Regulation 2026/78 says nothing about units already sold, and they were lawful when sold, so in our reading it does not itself require a recall. Decide and record it with your safety assessor, and inform the authorities if the product presents a risk.
Can I relabel the stock instead?
No, not where the problem is the composition. A new label cannot make a prohibited substance or an over-limit level compliant. Relabelling only helps where the defect is in the labelling itself.
Who pays for blocked stock held by a retailer?
The regulation stops the retailer selling it but does not allocate the cost. That is down to your contract. Without a regulatory withdrawal clause, retailers will usually claim a credit from the brand.
Official sources and legislation
- Commission Regulation (EU) 2026/78 (Omnibus VIII), Official Journal text, Articles 1 and 2 and recital 24
- Commission Delegated Regulation (EU) 2024/2564 (CLP classifications), Official Journal text
- Regulation (EC) No 1223/2009, EU consolidated version of 18 May 2026 (Articles 2, 5, 6, 14, 15 and 25)
- Commission Regulation (EU) 2024/858 (nanomaterials), Official Journal text
- Commission Regulation (EU) 2023/1545 (fragrance allergen labelling), Official Journal text
- SI 2026/109, Cosmetic Products Regulation (Restriction of Chemical Substances) (Amendment and Transitional Provisions) (No. 2) Regulations 2026
- SI 2026/23, Cosmetic Products Regulation (Restriction of Chemical Substances) (Amendment and Transitional Provisions) Regulations 2026
- Regulation (EC) No 1223/2009 as it applies in Great Britain, Article 2 (definitions)
- Regulation (EC) No 1223/2009 as it applies in Great Britain, Article 6 (distributors)
- Regulation (EC) No 1223/2009 as it applies in Great Britain, Article 16 (nanomaterials)
- GOV.UK: Making cosmetic products available to consumers in Great Britain
Join the conversation